These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33148437)

  • 1. Targeting ageing and preventing organ degeneration with metformin.
    Sunjaya AP; Sunjaya AF
    Diabetes Metab; 2021 Feb; 47(1):101203. PubMed ID: 33148437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing.
    Prattichizzo F; Giuliani A; Mensà E; Sabbatinelli J; De Nigris V; Rippo MR; La Sala L; Procopio AD; Olivieri F; Ceriello A
    Ageing Res Rev; 2018 Dec; 48():87-98. PubMed ID: 30336272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
    Campbell JM; Bellman SM; Stephenson MD; Lisy K
    Ageing Res Rev; 2017 Nov; 40():31-44. PubMed ID: 28802803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan.
    Mohammed I; Hollenberg MD; Ding H; Triggle CR
    Front Endocrinol (Lausanne); 2021; 12():718942. PubMed ID: 34421827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
    Rozengurt E; Sinnett-Smith J; Kisfalvi K
    Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin in selected malignancies in women.
    Markowska A; Stanislawiak-Rudowicz J; Kasprzak T; Markowska J; Szarszewska M
    Ginekol Pol; 2022; 93(5):416-421. PubMed ID: 35072253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB as the mediator of metformin's effect on ageing and ageing-related diseases.
    Kanigur Sultuybek G; Soydas T; Yenmis G
    Clin Exp Pharmacol Physiol; 2019 May; 46(5):413-422. PubMed ID: 30754072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin: Is it a drug for all reasons and diseases?
    Triggle CR; Mohammed I; Bshesh K; Marei I; Ye K; Ding H; MacDonald R; Hollenberg MD; Hill MA
    Metabolism; 2022 Aug; 133():155223. PubMed ID: 35640743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin in cancer.
    Mallik R; Chowdhury TA
    Diabetes Res Clin Pract; 2018 Sep; 143():409-419. PubMed ID: 29807101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight.
    Turkistani A; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Bahaa MM; Al-Windy S; Batiha GE
    Immun Inflamm Dis; 2024 Aug; 12(8):e1346. PubMed ID: 39092773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Effects of Metformin in the Failing Heart.
    Dziubak A; Wójcicka G; Wojtak A; Bełtowski J
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin: do we finally have an anti-aging drug?
    Anisimov VN
    Cell Cycle; 2013 Nov; 12(22):3483-9. PubMed ID: 24189526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
    Molavi B; Rassouli N; Bagwe S; Rasouli N
    Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is metformin a geroprotector? A peek into the current clinical and experimental data.
    Zajda A; Huttunen KM; Sikora J; Podsiedlik M; Markowicz-Piasecka M
    Mech Ageing Dev; 2020 Oct; 191():111350. PubMed ID: 32905803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.
    Samaras K; Makkar S; Crawford JD; Kochan NA; Wen W; Draper B; Trollor JN; Brodaty H; Sachdev PS
    Diabetes Care; 2020 Nov; 43(11):2691-2701. PubMed ID: 32967921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.